Related Experiment Video
Updated: Jun 7, 2026

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
Published on: August 20, 2007
The Immune Tolerance Network at 10 years: tolerance research at the bedside
Jeffrey A Bluestone1, Hugh Auchincloss, Gerald T Nepom
1Diabetes Center and Department of Medicine, University of California, San Francisco, San Francisco, California 94143, USA. jeff.bluestone@ucsf.edu
Abstract:
Immune tolerance-inducing therapies reprogramme immune cells to eliminate pathogenic immune responses while preserving protective immunity. The Immune Tolerance Network (ITN), sponsored by the US National Institutes of Health, was established in 1999 to evaluate new tolerance-inducing therapies and carry out mechanistic studies using a unique interactive approach in partnership with industry, academia and foundations. Ten years later, the ITN has carried out approximately 36 clinical trials and tolerance studies examining innovative tolerogenic approaches in the settings of allergy, autoimmune diseases and organ transplantation. ITN investigators have published more than 80 original research papers based on this work. This Timeline article summarizes the progress and challenges of clinical research in the ITN.
More Related Videos
Related Concept Videos
Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
Cell-mediated Immune Responses
Cells of the Adaptive Immune Response

